Cargando…

Altered peptide ligands can control CD4 T lymphocyte differentiation in vivo

Antigen priming of naive CD4 T cells can generate effector CD4 T cells that produce interleukin 4 (T helper [Th]2-like) or interferon-gamma (Th1-like). Using a system in which priming leads to responses dominated by one or the other of these cell types, we show that varying either the antigenic pept...

Descripción completa

Detalles Bibliográficos
Formato: Texto
Lenguaje:English
Publicado: The Rockefeller University Press 1995
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2191965/
https://www.ncbi.nlm.nih.gov/pubmed/7699337
_version_ 1782147128989057024
collection PubMed
description Antigen priming of naive CD4 T cells can generate effector CD4 T cells that produce interleukin 4 (T helper [Th]2-like) or interferon-gamma (Th1-like). Using a system in which priming leads to responses dominated by one or the other of these cell types, we show that varying either the antigenic peptide or the major histocompatibility complex class II molecule can determine whether Th1-like or Th2-like responses are obtained. Our results show that peptide/major histocompatibility complex class II complexes that interact strongly with the T cell receptor favor generation of Th1-like cells, while those that bind weakly favor priming of Th2-like T cells. Thus, signals from the T cell receptor can influence the differentiation of CD4 T cells into specific types of effector cells.
format Text
id pubmed-2191965
institution National Center for Biotechnology Information
language English
publishDate 1995
publisher The Rockefeller University Press
record_format MEDLINE/PubMed
spelling pubmed-21919652008-04-16 Altered peptide ligands can control CD4 T lymphocyte differentiation in vivo J Exp Med Articles Antigen priming of naive CD4 T cells can generate effector CD4 T cells that produce interleukin 4 (T helper [Th]2-like) or interferon-gamma (Th1-like). Using a system in which priming leads to responses dominated by one or the other of these cell types, we show that varying either the antigenic peptide or the major histocompatibility complex class II molecule can determine whether Th1-like or Th2-like responses are obtained. Our results show that peptide/major histocompatibility complex class II complexes that interact strongly with the T cell receptor favor generation of Th1-like cells, while those that bind weakly favor priming of Th2-like T cells. Thus, signals from the T cell receptor can influence the differentiation of CD4 T cells into specific types of effector cells. The Rockefeller University Press 1995-04-01 /pmc/articles/PMC2191965/ /pubmed/7699337 Text en This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/4.0/).
spellingShingle Articles
Altered peptide ligands can control CD4 T lymphocyte differentiation in vivo
title Altered peptide ligands can control CD4 T lymphocyte differentiation in vivo
title_full Altered peptide ligands can control CD4 T lymphocyte differentiation in vivo
title_fullStr Altered peptide ligands can control CD4 T lymphocyte differentiation in vivo
title_full_unstemmed Altered peptide ligands can control CD4 T lymphocyte differentiation in vivo
title_short Altered peptide ligands can control CD4 T lymphocyte differentiation in vivo
title_sort altered peptide ligands can control cd4 t lymphocyte differentiation in vivo
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2191965/
https://www.ncbi.nlm.nih.gov/pubmed/7699337